CHALLENGES IN THE DEVELOPMENT OF VACCINE VIRUS STRAINS FOR LIVE ATTENUATED INFLUENZA VACCINE BASED ON POTENTIALLY PANDEMIC INFLUENZA VIRUSES


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Objective. To provide the currently achieved results of searches for safe in ovo development of candidate strains for live attenuated influenza vaccine based on H5N1 viruses with a high pandemic potential. Materials and methods. Candidate strains as a source of antigenic determinants were used to obtain inactivated H5N1 influenza vaccine containing six internal genes from A/Puerto Rico/8/34 (PR8) influenza virus. The PR8 virus genes were replaced by the appropriate genome segments of the attenuated donor strain of the Russian live influenza vaccine A/Leningrad/134/17/57 (H2N2) through reassortment. Results. A strong coupling was found between the genome segments encoding the proteins NA and PB2 and the reassortments inherited strictly jointly from one of the parental viruses. Temperature-sensitive and cold-adapted 7:1 reassortment virus strains were obtained, which inherited only the HA gene from avian influenza viruses and all other genes from the attenuated donor strain. Conclusion. Notwithstanding the fact that 6:2 reassortment strains could not be obtained, we suppose that 7:1 reassortants based on highly pathogenic avian influenza virus strains in case of pandemic emergence can serve as a basis for developing live attenuated influenza vaccine against potentially pandemic avian influenza A (H5N1).

全文:

受限制的访问

作者简介

E. BAZHENOVA

Research Institute of Experimental Medicine, North-Western Branch, Russian Academy of Medical Sciences

Email: sonya.01.08@mail.ru
Saint Petersburg

N. LARIONOVA

Research Institute of Experimental Medicine, North-Western Branch, Russian Academy of Medical Sciences

Email: nvlarionova@mail.ru
Saint Petersburg

E. FEDOROVA

Research Institute of Experimental Medicine, North-Western Branch, Russian Academy of Medical Sciences

Email: dosobaki@gmail.com
Saint Petersburg

I. DUBROVINA

Research Institute of Experimental Medicine, North-Western Branch, Russian Academy of Medical Sciences

Email: ropsha.home@rambler.ru
Saint Petersburg

I. KISELEVA

Research Institute of Experimental Medicine, North-Western Branch, Russian Academy of Medical Sciences

Email: irina.v.kiseleva@mail.ru
Saint Petersburg

L. RUDENKO

Research Institute of Experimental Medicine, North-Western Branch, Russian Academy of Medical Sciences

Email: vaccine@mail.ru
Saint Petersburg

参考

  1. WHO. Initiative for Vaccine Research (IVR). Options for Live Attenuated Influenza Vaccines (LAIV) In the Control of Epidemic and Pandemic Influenza 12—13 June 2007. http://www.who.int/vaccine_research/diseases/influenza/ meeting_120707/en/index.html.
  2. WHO. Global action plan to increase vaccine supply for influenza vaccines. 2006, Geneva, Belgium. http:// whqlibdoc.who.int/hq/2006/WH0_IVB_06.13_eng. pdf.
  3. Александрова Г.И. Применение метода генетической рекомбинации для получения вакцинных штаммов вируса гриппа. Вопр. вирусол. 1977; 4: 387—395.
  4. Wareing M. D., Watson J.M., Brooks M. J., Tannock G. A. Immunogenic and isotype—specific responses to Russian and US cold—adapted influenza a vaccine donor strains A/Leningrad/134/17/57, A/Leningrad/134/47/57, and A/ Ann Arbor/6/60 (H2N2) in mice. J. Med. Virol. 2001; 65: 171—177.
  5. Klimov A.I., Cox N.J. PCR restriction analysis of genome composition and stability of cold—adapted reassortant live influenza vaccines. J. Virol. Methods 1995; 52: 41—49.
  6. Об утверждении правил лабораторной практики: приказ Минздравсоцразвития России № 708н от 23.08.2010. http://www.rg.ru/2010/10/22/laboratornaya— praktika—dok.html
  7. Методы определения показателей качества иммунобиологических препаратов для профилактики и диагностики гриппа: Метод. указания МУ №3.3.2.175803 от 28.09.2003.
  8. WHO. Statement by WHO Director—General, Dr Margaret Chan 11 June 2009. World now at the start of 2009 influenza pandemic. http://www.who.int/mediacentre/news/ statements/2009/h1n1_pandemic_phase6_20090611/en/ index.html
  9. WHO. Global alert and response (GAR). Confirmed Human Cases of Avian Influenza A (H5N1). http://www.who.int/ csr/disease/avian_influenza/country/en/
  10. Zitzow L.A., Rowe T., Morken T. et al. Pathogenesis of avian influenza A (H5N1) viruses in ferrets. J. Virol. 2002; 76(9): 4420—4429.
  11. Subbarao K., Chen H., Swayne D. et al. Evaluation of genetically modified reassortant H5N1 influenza virus vaccine candidate generated by plasmid—based reverse genetics. Virology 2003; 305: 192—200.
  12. Rudenko L., Desheva J., Korovkin S. et al. Safety and immunogenicity of live attenuated influenza reassortant H5 vaccine (phase I—II clinical trials). IRV 2008; 2: 203—209.
  13. «Ультрагривак» — моновакцина типа A(H5N2), для профилактики птичьего гриппа. Регистрационное свидетельство ЛСР—002340/09 от 25.03.2009.) http://grls. rosminzdrav.ru/Grls_View.aspx?idReg=7154&t=eb726df2— f7aa—41ce—b060—4f9340fe025a

补充文件

附件文件
动作
1. JATS XML

版权所有 © Bionika Media, 2012